(ALLO) Allogene Therapeutics - Ratings and Ratios

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage immuno-oncology company pioneering the development of genetically engineered allogeneic CAR T cell therapies. These therapies are designed to address significant unmet needs in cancer treatment by leveraging the advantages of allogeneic cells, which eliminate the need for personalized manufacturing and offer a more scalable and accessible solution for patients. The companys lead product candidate, UCART19, is an allogeneic CAR T cell therapy targeting CD19 for the treatment of relapsed or refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both pediatric and adult patients. UCART19 has demonstrated clinical activity in early trials, with a focus on improving outcomes for patients who have limited treatment options.

Allogenes pipeline extends beyond UCART19, with multiple candidates in various stages of development. Cemacabtagene ansegedleucel, another CD19-targeted CAR T therapy, is being investigated for large B-cell lymphoma and is currently in a Phase 1b clinical trial for chronic lymphocytic leukemia (CLL). The company is also advancing ALLO-715 and ALLO-605, both targeting BCMA for the treatment of relapsed or refractory multiple myeloma, with ALLO-715 in a Phase 1 trial and ALLO-605 in an earlier Phase I study. Additionally, ALLO-647, an anti-CD52 monoclonal antibody, is part of the companys broader portfolio, which includes preclinical programs targeting CD70 for renal cell carcinoma, DLL3 for small cell lung cancer, and Claudin 18.2 for gastric and pancreatic cancers.

Allogene has established strategic collaborations to enhance its research and development capabilities. These include partnerships with Pfizer, Servier, Cellectis, and Notch Therapeutics, as well as a collaboration with The University of Texas MD Anderson Cancer Center to explore allogeneic CAR T cell therapies. The company also has a partnership with Foresight Diagnostics to develop minimal residual disease (MRD)-based diagnostics to support its ALPHA3 clinical trial program. Founded in 2017 and headquartered in South San Francisco, California, Allogene is positioned as a leader in the allogeneic cell therapy space, with a focus on improving patient outcomes through innovative and scalable therapies.

Ticker Symbol: ALLO
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Biotechnology

Average Volume 20d: 10,140,104
Last Price: 1.95
SMA 20: 1.87
SMA 50: 1.95
SMA 200: 2.44
ATR: 0.24

Market Cap: 454.99M USD
P/E: 0.00
P/E Forward: 0.00
P/B: 0.98
P/S: None
RoE: -61.12

3-Month Forecast:
Based on the technical and fundamental data, ALLO is expected to face headwinds in the near term. The stock price has been trending below its 200-day SMA of 2.44, indicating bearish momentum. With the 20-day SMA at 1.87 and the 50-day SMA at 1.95, the stock may struggle to break above resistance levels. The average true range (ATR) of 0.24 suggests moderate volatility, with potential downside risks tied to the companys negative return on equity (RoE) of -61.12 and the lack of positive earnings multiples. While the price-to-book ratio of 0.98 indicates the stock may be fairly valued, the absence of forward P/E and P/S metrics reflects the speculative nature of investing in a clinical-stage biotechnology company. Investors should monitor clinical trial progress and collaboration outcomes for potential catalysts.